CNTN4 as a novel target for solid cancer with antibody-drug conjugate

被引：0
|
作者：
Cha, Mi Young
Kim, Hyunuk
Byun, Seungmin
Ha, Youngeun
Park, Kitae
Yu, Hyunkyung
Jeon, Bu-Nam
Kim, Mira
Moon, Soojung
Park, Kyung Mi
Park, Hansoo
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
740
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Antibody-Drug Conjugate to Treat Meningiomas
    Chen, Kai
    Si, Yingnan
    Ou, Jianfa
    Guan, Jia-Shiung
    Kim, Seulhee
    Ernst, Patrick
    Zhang, Ya
    Zhou, Lufang
    Han, Xiaosi
    Liu, Xiaoguang
    PHARMACEUTICALS, 2021, 14 (05)
  • [42] The target atlas for antibody-drug conjugates across solid cancers
    Fang, Jiacheng
    Guo, Lei
    Zhang, Yanhao
    Guo, Qing
    Wang, Ming
    Wang, Xiaoxiao
    CANCER GENE THERAPY, 2024, 31 (02) : 273 - 284
  • [43] The target atlas for antibody-drug conjugates across solid cancers
    Jiacheng Fang
    Lei Guo
    Yanhao Zhang
    Qing Guo
    Ming Wang
    Xiaoxiao Wang
    Cancer Gene Therapy, 2024, 31 : 273 - 284
  • [44] Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells
    Sharma, Sharad
    Li, Zhe
    Bussing, David
    Shah, Dhaval K.
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (05) : 368 - 377
  • [45] Development of AVID100, a novel antibody-drug conjugate for the treatment of EGFR expressing solid tumors
    O'Connor-McCourt, M.
    Koropatnick, J.
    Maleki, S.
    Figueredo, R.
    Tikhomirov, I.
    Jaramillo, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S147 - S147
  • [46] LIV-1 antibody-drug conjugate: A novel therapeutic agent for breast and prostate cancer
    Sussman, Django
    Nesterova, Albina
    Westendorf, Lori
    Duniho, Steven
    Anderson, Martha
    Mbow, Brianna
    Gregoire, Ashley
    Hunter, Joshua H.
    Whiting, Nancy
    Corey, Eva
    Vessella, Robert L.
    Benjamin, Dennis R.
    Smith, Leia M.
    CANCER RESEARCH, 2011, 71
  • [47] CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer
    Shiomi, Mayu
    Matsuzaki, Shinya
    Serada, Satoshi
    Matsuo, Koji
    Mizuta-Odani, Chihiro
    Jitsumori, Mariko
    Nakae, Ruriko
    Matsuzaki, Satoko
    Nakagawa, Satoshi
    Hiramatsu, Kosuke
    Miyoshi, Ai
    Kobayashi, Eiji
    Kimura, Toshihiro
    Ueda, Yutaka
    Yoshino, Kiyoshi
    Naka, Tetsuji
    Kimura, Tadashi
    CANCER SCIENCE, 2021, 112 (09) : 3655 - 3668
  • [48] The antibody-drug conjugate target landscape across a broad range of tumour types
    Moek, K. L.
    de Groot, D. J. A.
    de Vries, E. G. E.
    Fehrmann, R. S. N.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3083 - 3091
  • [49] A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy
    Boehnke, Niels
    Berger, Markus
    Griebenow, Nils
    Rottmann, Antje
    Erkelenz, Michael
    Hammer, Stefanie
    Berndt, Sandra
    Guenther, Judith
    Wengner, Antje M.
    Stelte-Ludwig, Beatrix
    Mahlert, Christoph
    Greven, Simone
    Dietz, Lisa
    Jorissen, Hannah
    Barak, Naomi
    Boemer, Ulf
    Hillig, Roman C.
    Eberspaecher, Uwe
    Weiske, Jorg
    Giese, Anja
    Mumberg, Dominik
    Nising, Carl Friedrich
    Weinmann, Hilmar
    Sommer, Anette
    BIOCONJUGATE CHEMISTRY, 2022, 33 (06) : 1210 - 1221
  • [50] Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML
    Abrams, Tinya J.
    Niu, Xiaohong
    Embry, Millicent
    Kline, Janine
    Patawaran, Montesa
    Fanton, Christie
    Ison-Dugenny, Marjorie
    Schneider, Tracy
    Miller, Kathy
    Wang, Zhen
    Ghoddusi, Majid
    Cohen, Steven
    Hong, E. Erica
    Lees, Emma
    Schleyer, Siew
    CANCER RESEARCH, 2015, 75
12345